Tag: 2253

2253

DTC Advertising

OPDP, Lilly Come to Terms Over TV Ads for Migraine Drug

OPDP, Lilly Come to Terms Over TV Ads for Migraine Drug

Jan. 17, 2022 – A common theme among the enforcement letters issued by the FDA’s Office of Prescription Drug Promotion (OPDP) is the manner in which a drug’s promotional materials present product benefits while omitting product risk information. In its final Untitled Letter of 2021 to Eli Lilly, OPDP repeated this message, but the company’s […]

Read more